BioPharmSignal logoBioPharmSignal

Biotech News

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

Xenon (XENE)XenonClinical readout

XEN1701 achieved target profile, including desired Na V 1.7 receptor occupancy in both the peripheral and central nervous system, and was generally well-tolerated with no notable autonomic cardiovascular effects XEN1120 achieved plasma levels predictive of analgesic effects based on preclinical

Related news

ALKSAlkermes plc2026-09-21 11:00 EST

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

TNXPTonix Pharmaceuticals2026-10-27 11:00 EST

Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain

VTGNVistagen Therapeutics, Inc.2026-09-22 12:30 EST

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

JNJJohnson & Johnson2026-10-19 12:23 EST

Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula

TEVATeva Pharmaceutical Industries2026-11-02 13:00 EST

Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis

ALKSAlkermes plc2026-10-30 11:00 EST

Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)

ABOSAcumen Pharmaceuticals2026-10-22 11:30 EST

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

TEVATeva Pharmaceutical Industries2026-09-18 20:30 EST

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

TNXPTonix Pharmaceuticals2026-10-19 11:00 EST

Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain

ADXNAddex Therapeutics2026-10-08 05:00 EST

Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia

View all latest news

Xenon

Ion-Channel Therapeutics Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels. Its pipeline addresses epilepsy, depression and pain through mechanisms intended to control abnormal electrical signaling. Azetukalner Azetukalner is a selective Kv7 potassium-channel opener intended to reduce excessive neuronal firing....

Recent company news

XENEXenon2026-11-03 21:01 EST

Xenon to Present at Upcoming Investor Conferences

XENEXenon2026-11-02 21:02 EST

Xenon to Report Q3 2026 Financial Results on November 9, 2026

XENEXenon2026-10-30 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XENEXenon2026-10-29 12:30 EST

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

XENEXenon2026-10-02 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
37.68 USD
Market cap
5.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States